Form 4: Spyre Therapeutics Director Sells Shares

Sentiment:

Insider Transaction (Form 4)


Jeffrey W. Albers, a Director of Spyre Therapeutics, Inc., sold 23,000 shares of common stock on August 7, 2026.

Summary

  • Option exercise/conversion: acquired 5,000 Common Stock at $10.39 ($51,950) on August 7, 2026; holds 5,000 after (Direct).
  • Open-market sale: disposed of 5,000 Common Stock at $104.47 ($522,350) on August 7, 2026 (Direct).
  • Open-market sale: disposed of 8,000 Common Stock at $104.38 ($835,040) on August 7, 2026; holds 19,360 after (Indirect).
  • Open-market sale: disposed of 10,000 Common Stock at $104.68 ($1,046,800) on August 7, 2026; holds 9,360 after (Indirect).
  • Option exercise/conversion: disposed of 5,000 Stock Option (Right to Buy) on August 7, 2026; holds 45,000 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,404,190 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Jeffrey W. Albers — Director

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-07Option exercise/conversionCommon Stock5,000$10$52.0K5,000
2026-08-07Open-market saleCommon Stock5,000$104$522.4K0
2026-08-07Open-market saleCommon Stock8,000$104$835.0K19,360
2026-08-07Open-market saleCommon Stock10,000$105$1.0M9,360
2026-08-07Option exercise/conversionStock Option (Right to Buy)5,000——45,000

Key Dates

DateDescription
2026-08-07Option exercise/conversion (5,000 shares)
2026-08-07Open-market sale (5,000 shares)
2026-08-07Open-market sale (8,000 shares)
2026-08-07Open-market sale (10,000 shares)
2026-08-07Option exercise/conversion (5,000 shares)

Keywords

insider transaction, Form 4, SYRE, Spyre Therapeutics, Inc., bearish, Jeffrey W. Albers

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.